AbstractThe role of inactivation as a central mechanism in blockade of the cardiac Na+ channel by antiarrhythmic drugs remains uncertain. We have used whole-cell and single channel recordings to examine the block of wild-type and inactivation-deficient mutant cardiac Na+ channels, IFM/QQQ, stably expressed in HEK-293 cells. We studied the open-channel blockers disopyramide and flecainide, and the lidocaine derivative RAD-243. All three drugs blocked the wild-type Na+ channel in a use-dependent manner. There was no use-dependent block of IFM/QQQ mutant channels with trains of 20 40-ms pulses at 150-ms interpulse intervals during disopyramide exposure. Flecainide and RAD-243 retained their use-dependent blocking action and accelerated macrosc...
The sodium (Na) channel is the fundamental unit of excitability in heart muscle. This channel has be...
rapid structural changes in response to the changing electrical field in the myocardium. Inherited m...
1 RSD 921 is a novel, structurally unique, class I Na+ channel blocking drug under development as a ...
Effects of flecainide, a potent antiarrhythmic agent, on sodium channel availability was investigate...
Flecainide block of Na1 current (INa) was investigated in wild-type (WT) or the long QT syndrome 3 (...
Lidocaine block of the cardiac sodium channel is believed to be primarily a function of channel stat...
Na(+) channel blockers such as flecainide have found renewed usefulness in the diagnosis and treatme...
Background—The development of selective atrial antiarrhythmic agents is a current strategy for suppr...
Introduction Atrial fibrillation (AF) affects over 1% of the population and is a leading cause of s...
AbstractWhen depolarized from typical resting membrane potentials (Vrest ∼ −90mV), cardiac sodium (N...
We have identified two kinetically distinct modes of block, by lidocaine, of cardiac sodium channels...
The genetic disorder catecholaminergic polymorphic ventricular tachycardia (CPVT) causes the functio...
Antiarrhythmic drugs, designed to prevent or suppress cardiac arrhythmias, may cause the worsening o...
Lidocaine is a widely used local anesthetic and antiarrhythmic drug that is believed to exert its cl...
Mexiletine and lidocaine are widely used class IB anti-arrhythmic drugs that are considered to act b...
The sodium (Na) channel is the fundamental unit of excitability in heart muscle. This channel has be...
rapid structural changes in response to the changing electrical field in the myocardium. Inherited m...
1 RSD 921 is a novel, structurally unique, class I Na+ channel blocking drug under development as a ...
Effects of flecainide, a potent antiarrhythmic agent, on sodium channel availability was investigate...
Flecainide block of Na1 current (INa) was investigated in wild-type (WT) or the long QT syndrome 3 (...
Lidocaine block of the cardiac sodium channel is believed to be primarily a function of channel stat...
Na(+) channel blockers such as flecainide have found renewed usefulness in the diagnosis and treatme...
Background—The development of selective atrial antiarrhythmic agents is a current strategy for suppr...
Introduction Atrial fibrillation (AF) affects over 1% of the population and is a leading cause of s...
AbstractWhen depolarized from typical resting membrane potentials (Vrest ∼ −90mV), cardiac sodium (N...
We have identified two kinetically distinct modes of block, by lidocaine, of cardiac sodium channels...
The genetic disorder catecholaminergic polymorphic ventricular tachycardia (CPVT) causes the functio...
Antiarrhythmic drugs, designed to prevent or suppress cardiac arrhythmias, may cause the worsening o...
Lidocaine is a widely used local anesthetic and antiarrhythmic drug that is believed to exert its cl...
Mexiletine and lidocaine are widely used class IB anti-arrhythmic drugs that are considered to act b...
The sodium (Na) channel is the fundamental unit of excitability in heart muscle. This channel has be...
rapid structural changes in response to the changing electrical field in the myocardium. Inherited m...
1 RSD 921 is a novel, structurally unique, class I Na+ channel blocking drug under development as a ...